S&P 500   4,320.06 (-0.23%)
DOW   33,963.84 (-0.31%)
QQQ   357.91 (+0.01%)
AAPL   174.79 (+0.49%)
MSFT   317.01 (-0.79%)
META   299.08 (+1.13%)
GOOGL   130.25 (-0.15%)
AMZN   129.12 (-0.16%)
TSLA   244.88 (-4.23%)
NVDA   416.10 (+1.45%)
NIO   8.53 (+0.95%)
BABA   88.30 (+4.98%)
AMD   96.20 (+0.09%)
T   15.12 (-1.24%)
F   12.43 (+1.89%)
MU   68.88 (+1.44%)
CGC   0.84 (+9.48%)
GE   111.25 (-1.54%)
DIS   81.25 (-1.79%)
AMC   7.62 (-1.04%)
PFE   32.69 (-0.49%)
PYPL   57.88 (-1.26%)
NFLX   379.81 (-1.13%)
S&P 500   4,320.06 (-0.23%)
DOW   33,963.84 (-0.31%)
QQQ   357.91 (+0.01%)
AAPL   174.79 (+0.49%)
MSFT   317.01 (-0.79%)
META   299.08 (+1.13%)
GOOGL   130.25 (-0.15%)
AMZN   129.12 (-0.16%)
TSLA   244.88 (-4.23%)
NVDA   416.10 (+1.45%)
NIO   8.53 (+0.95%)
BABA   88.30 (+4.98%)
AMD   96.20 (+0.09%)
T   15.12 (-1.24%)
F   12.43 (+1.89%)
MU   68.88 (+1.44%)
CGC   0.84 (+9.48%)
GE   111.25 (-1.54%)
DIS   81.25 (-1.79%)
AMC   7.62 (-1.04%)
PFE   32.69 (-0.49%)
PYPL   57.88 (-1.26%)
NFLX   379.81 (-1.13%)
S&P 500   4,320.06 (-0.23%)
DOW   33,963.84 (-0.31%)
QQQ   357.91 (+0.01%)
AAPL   174.79 (+0.49%)
MSFT   317.01 (-0.79%)
META   299.08 (+1.13%)
GOOGL   130.25 (-0.15%)
AMZN   129.12 (-0.16%)
TSLA   244.88 (-4.23%)
NVDA   416.10 (+1.45%)
NIO   8.53 (+0.95%)
BABA   88.30 (+4.98%)
AMD   96.20 (+0.09%)
T   15.12 (-1.24%)
F   12.43 (+1.89%)
MU   68.88 (+1.44%)
CGC   0.84 (+9.48%)
GE   111.25 (-1.54%)
DIS   81.25 (-1.79%)
AMC   7.62 (-1.04%)
PFE   32.69 (-0.49%)
PYPL   57.88 (-1.26%)
NFLX   379.81 (-1.13%)
S&P 500   4,320.06 (-0.23%)
DOW   33,963.84 (-0.31%)
QQQ   357.91 (+0.01%)
AAPL   174.79 (+0.49%)
MSFT   317.01 (-0.79%)
META   299.08 (+1.13%)
GOOGL   130.25 (-0.15%)
AMZN   129.12 (-0.16%)
TSLA   244.88 (-4.23%)
NVDA   416.10 (+1.45%)
NIO   8.53 (+0.95%)
BABA   88.30 (+4.98%)
AMD   96.20 (+0.09%)
T   15.12 (-1.24%)
F   12.43 (+1.89%)
MU   68.88 (+1.44%)
CGC   0.84 (+9.48%)
GE   111.25 (-1.54%)
DIS   81.25 (-1.79%)
AMC   7.62 (-1.04%)
PFE   32.69 (-0.49%)
PYPL   57.88 (-1.26%)
NFLX   379.81 (-1.13%)
NASDAQ:TLRY

Tilray (TLRY) Stock Forecast, Price & News

$2.40
+0.02 (+0.84%)
(As of 05:42 PM ET)
Compare
Today's Range
$2.35
$2.47
50-Day Range
$1.65
$3.31
52-Week Range
$1.50
$5.12
Volume
18.99 million shs
Average Volume
20.24 million shs
Market Capitalization
$1.69 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.07

Tilray MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
27.7% Upside
$3.07 Price Target
Short Interest
Healthy
12.67% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.38mentions of Tilray in the last 14 days
Based on 16 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.18) to ($0.10) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.99 out of 5 stars

Consumer Staples Sector

91st out of 123 stocks

Medicinals & Botanicals Industry

7th out of 11 stocks


TLRY stock logo

About Tilray (NASDAQ:TLRY) Stock

Tilray Inc is a pharmaceutical and cannabis company founded in 2013 and headquartered in Nanaimo, Canada. The company operates in the United States, Europe, Canada, Australia and Latin America. Tilray is known for producing and distributing medical and recreational cannabis products.

Tilray Inc is primarily engaged in the production, research, development and distribution of medical and recreational cannabis products. The company's product portfolio includes dried cannabis, cannabis oil and capsules. Tilray also produces and distributes hemp-based food products, such as hemp hearts and hemp protein powder.

Tilray operates in two segments: Cannabis and Hemp. The Cannabis segment includes medical and adult-use cannabis, and the Hemp segment includes hemp food products and hemp-based CBD products.

The company's stock price has fluctuated significantly over the past few years. Tilray Inc accredits these fluctuations to changing legal landscapes, changing demands of its clients and increasing competition.

Tilray Inc faces significant competition in the cannabis and hemp industries. The company competes with other cannabis producers, such as Canopy Growth Corporation and Aurora Cannabis Inc, as well as with companies that produce hemp-based products, such as Hemp Inc and Charlotte's Web Holdings Inc.

Tilray also faces competition from illegal cannabis producers, particularly in countries where cannabis is still illegal. The company's success will depend on its ability to compete effectively in the legal cannabis and hemp markets and to expand into new markets as legalization continues.

Tilray Inc's growth prospects are closely tied to legalizing cannabis and hemp products. The company has already expanded its operations into several countries where cannabis is legal, such as Canada, the United States and Germany.

Tilray's merger with Aphria Inc in May 2021 has also given the company multiple growth opportunities. The merger created the world's largest cannabis company, with a market capitalization of over $5 billion. The combined company has a strong presence in Canada, Europe and the United States and is well-positioned to benefit from the continued legalization of cannabis and hemp products.

The company's focus on research and development also provides significant growth opportunities. Tilray has a research and development facility in Canada, conducting clinical trials to evaluate the effectiveness of cannabis and hemp-based products for medical purposes.

Tilray Inc faces several risks and challenges, particularly in the current regulatory environment. Cannabis and hemp products are still illegal in many countries, which limits the company's growth opportunities. Even in countries where cannabis is legal, the regulatory environment can be complex and rapidly evolving, creating challenges for the company's operations.

Tilray's success also depends on its ability to compete effectively in a crowded market. The company faces competition from other cannabis and hemp producers, as well as from illegal producers. The company's success will depend on its ability to differentiate itself from its competitors and build a strong brand that resonates with consumers.

TLRY Price History

TLRY Stock News Headlines

Cannabis Stocks: Green Gold Rush or Risk Off? (TLRY)
Cannabis stocks, including CGC, TLRY, and ACB, have experienced significant gains over the past month, posting double to triple-digit increases.
Will This New Development Mean A Big Rally In Cannabis Stocks? (TLRY)
Numerous cannabis stocks surged after a government agency recommended removing marijuana from Schedule 1, potentially paving the way for industry growth.
BREAKING: Tiny biotech successfully treats blindness
There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.
Closing Bell: Tilray Inc down on Thursday (TLRY)
Tilray Brands: Top 10 Undervalued Growth Stocks on TSX (TLRY)
What's Going On With Tilray Brands Stock? Buzzkill
Where Will Tilray Brands Be in 1 Year?
BREAKING: Tiny biotech successfully treats blindness
There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.
What's Going On With Tilray Brands Stock? The Blunt Truth
Tilray Brands Is Potentially Very Overpriced
Tilray (NASDAQ:TLRY) Shares Gap Up to $2.98
Tilray Sees Unusually High Options Volume (NASDAQ:TLRY)
Why Tilray Brands Stock Is Moving
Why Is Tilray (TLRY) Stock Up 7% Today?
See More Headlines
Receive TLRY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Tilray and its competitors with MarketBeat's FREE daily newsletter.

TLRY Company Calendar

Last Earnings
4/10/2023
Today
9/22/2023
Next Earnings (Confirmed)
10/04/2023
Fiscal Year End
5/31/2024

Industry, Sector and Symbol

Industry
Medicinals & botanicals
Sub-Industry
N/A
Current Symbol
NASDAQ:TLRY
Fax
N/A
Employees
1,600
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$3.07
High Stock Price Forecast
$5.00
Low Stock Price Forecast
$2.00
Forecasted Upside/Downside
+27.7%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
8 Analysts

Profitability

Net Income
$-1,452,660,000.00
Net Margins
-226.15%
Pretax Margin
-231.24%

Debt

Sales & Book Value

Annual Sales
$627.12 million
Cash Flow
$0.00 per share
Book Value
$5.07 per share

Miscellaneous

Free Float
685,394,000
Market Cap
$1.69 billion
Optionable
Optionable
Beta
2.39
Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

  • Mr. Edward Wood Pastorius Jr. (Age 50)
    Chief Revenue Officer
  • Mr. Brendan  KennedyMr. Brendan Kennedy (Age 46)
    Pres, CEO & Director
  • Mr. Mark Castaneda (Age 53)
    CFO, Sec. & Treasurer
  • Dr. Catherine Jacobson
    Director of Clinical Research & Member of Medical Advisory Board













TLRY Stock - Frequently Asked Questions

Should I buy or sell Tilray stock right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Tilray in the last year. There are currently 1 sell rating, 6 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" TLRY shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TLRY, but not buy additional shares or sell existing shares.
View TLRY analyst ratings
or view top-rated stocks.

What is Tilray's stock price forecast for 2023?

8 Wall Street research analysts have issued 1-year price objectives for Tilray's stock. Their TLRY share price forecasts range from $2.00 to $5.00. On average, they expect the company's stock price to reach $3.07 in the next twelve months. This suggests a possible upside of 27.7% from the stock's current price.
View analysts price targets for TLRY
or view top-rated stocks among Wall Street analysts.

How have TLRY shares performed in 2023?

Tilray's stock was trading at $2.69 at the beginning of the year. Since then, TLRY shares have decreased by 10.8% and is now trading at $2.40.
View the best growth stocks for 2023 here
.

When is Tilray's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, October 4th 2023.
View our TLRY earnings forecast
.

How can I listen to Tilray's earnings call?

Tilray will be holding an earnings conference call on Wednesday, October 4th at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link.

How were Tilray's earnings last quarter?

Tilray Inc (NASDAQ:TLRY) released its quarterly earnings data on Monday, April, 10th. The company reported ($1.90) EPS for the quarter, missing analysts' consensus estimates of ($0.06) by $1.84. The company earned $145.59 million during the quarter, compared to analyst estimates of $150.13 million. Tilray had a negative trailing twelve-month return on equity of 3.45% and a negative net margin of 226.15%. The company's revenue was down 4.1% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.04 EPS.

What is Brendan Kennedy's approval rating as Tilray's CEO?

32 employees have rated Tilray Chief Executive Officer Brendan Kennedy on Glassdoor.com. Brendan Kennedy has an approval rating of 51% among the company's employees. This puts Brendan Kennedy in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Tilray own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Tilray investors own include Cronos Group (CRON), Aurora Cannabis (ACB), NVIDIA (NVDA), Alibaba Group (BABA), Advanced Micro Devices (AMD), Tesla (TSLA), Micron Technology (MU), Netflix (NFLX) and Block (SQ).

When did Tilray IPO?

(TLRY) raised $135 million in an initial public offering on Thursday, July 19th 2018. The company issued 9,000,000 shares at $14.00-$16.00 per share. Cowen and Company served as the underwriter for the IPO and Roth Capital Partners and Northland Securities were co-managers.

What is Tilray's stock symbol?

Tilray trades on the NASDAQ under the ticker symbol "TLRY."

Who are Tilray's major shareholders?

Tilray's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Bank Julius Baer & Co. Ltd Zurich (1.51%), Mirae Asset Global Investments Co. Ltd. (0.43%), BlackRock Inc. (0.38%), Swiss National Bank (0.20%), State Street Corp (0.19%) and TD Asset Management Inc (0.16%). Insiders that own company stock include Brendan Kennedy, Carl A Merton, Christine StClare and James R Meiers.
View institutional ownership trends
.

How do I buy shares of Tilray?

Shares of TLRY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Tilray's stock price today?

One share of TLRY stock can currently be purchased for approximately $2.40.

How much money does Tilray make?

Tilray (NASDAQ:TLRY) has a market capitalization of $1.69 billion and generates $627.12 million in revenue each year. The company earns $-1,452,660,000.00 in net income (profit) each year or ($2.29) on an earnings per share basis.

How many employees does Tilray have?

The company employs 1,600 workers across the globe.

How can I contact Tilray?

Tilray's mailing address is 1100 MAUGHAN ROAD, NANAIMO A1, V9X 1J2. The official website for the company is www.tilray.com. The company can be reached via phone at 206-432-9325.

This page (NASDAQ:TLRY) was last updated on 9/22/2023 by MarketBeat.com Staff

My Account -